Biodrugs

Papers
(The TQCC of Biodrugs is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond350
Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis297
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis127
Emerging Therapy in Osteoarthritis: Mesenchymal Stem Cells, Secretomes, and Using Hydrogels to Enhance Efficacy103
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome93
Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor92
New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making78
Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery62
Acknowledgement to Referees61
Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials60
In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart49
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies44
Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–202240
CAR-T Cells and the Kidney: Insights from the WHO Safety Database40
Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?38
The Present and Future of Monoclonal Antibody Therapies for Multiple Sclerosis36
Cell Engineering for Increasing Production of Recombinant Proteins in Mammalian Cells36
Correction: Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent Endometrial Cancer: A Nationwide Cohort Study in France36
Correction: Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review35
Progress and Challenges in the Treatment of Fabry Disease34
Malaria Vaccines: Progress to Date34
Characterization of Biosimilar Monoclonal Antibodies and Their Reference Products Approved in Japan to Reveal the Quality Characteristics in Post-approval Phase33
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?32
Effectiveness of Lebrikizumab Treatment for Patients with Atopic Dermatitis Switched from Dupilumab or Tralokinumab: A 48-Week Real-World Retrospective Study32
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer31
Interleukin-23 Inhibitors in Inflammatory Bowel Disease30
Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects30
Acknowledgement to Referees29
Real-World Evidence on the Effectiveness and Safety of Spesolimab in the Treatment of Generalized Pustular Psoriasis Flares: A Case Series29
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options28
Defining a Framework for Sustainable Global Biosimilars Markets Using Findings from a Targeted Literature Review28
Extracellular Vesicles Derived from Mesenchymal Stem Cells: A Potential Biodrug for Acute Respiratory Distress Syndrome Treatment26
Biochemical Amenability in Fabry Patients Under Chaperone Therapy—How and When to Test?26
Advanced Combination Therapy in Inflammatory Bowel Disease: What Does the Future Hold?25
Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network25
Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy25
Recombinant Protein Drugs: A 2025 Update25
Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa24
Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case Study24
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Stu23
Islet Cell Replacement and Regeneration for Type 1 Diabetes: Current Developments and Future Prospects21
Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight20
Tolerability and Reactogenicity Profile of mRNA SARS-Cov-2 Vaccines from a Mass Vaccination Campaign in a Tertiary Hospital: Between-Vaccine and Between-Population Prospective Observational Study (Vig20
Understanding IgM Structure and Biology to Engineer New Antibody Therapeutics20
The Use of Biologics for Thyroid Eye Disease19
TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review19
Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study19
Extracellular Vesicles and Immune Activation in Solid Organ Transplantation: The Impact of Immunosuppression18
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis18
Acute Kidney Injury from Intravitreal Anti-vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Controlled Trials18
Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database18
Next-Generation Anti-TNFα Agents: The Example of Ozoralizumab18
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine17
Biosimilar Uptake in Spain from 2016 to 2023: Analysis Based on Official Data Collection17
Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies16
Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs16
Going Beyond Host Defence Peptides: Horizons of Chemically Engineered Peptides for Multidrug-Resistant Bacteria15
Advances of Antimicrobial Peptides in the Treatment of Multidrug-Resistant Bacteria14
CRISPR-Cas System: A New Dawn to Combat Antibiotic Resistance14
Monoclonal Antibody Generation Using Single B Cell Screening for Treating Infectious Diseases14
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N: A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers13
Patients’ Perceptions of Biosimilars: A Systematic Review13
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease13
Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing13
Targeting the Inside of Cells with Biologicals: Toxin Routes in a Therapeutic Context13
0.96799683570862